1992
DOI: 10.3892/ijo.1.6.705
|View full text |Cite
|
Sign up to set email alerts
|

The Galactoside-Specific Lectin From Mistletoe as Biological Response Modifier

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
14
1
2

Year Published

1996
1996
2008
2008

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 21 publications
(17 citation statements)
references
References 0 publications
0
14
1
2
Order By: Relevance
“…A galactoside lectin of 70 kDa of MW, denominated L-Phl, was isolated from the extract. The level of purified product was much lower than that recorded for Viscum album lectin (Gabius et al, 1992).…”
Section: Discussioncontrasting
confidence: 69%
See 1 more Smart Citation
“…A galactoside lectin of 70 kDa of MW, denominated L-Phl, was isolated from the extract. The level of purified product was much lower than that recorded for Viscum album lectin (Gabius et al, 1992).…”
Section: Discussioncontrasting
confidence: 69%
“…Its extracts have been described to exert immunomodulatory effects (Bloksma et al, 1982;Gabius et al, 1992;Hajto, 1986) and a direct toxic effect on tumor cells (Janssen et al, 1993;Schaller et al, 1996). These capacities appear to be conferred by a galactoside-specific lectin (Beuth et al, 1996;Elsasser-Beile et al, 2000;Gabius et al, 1992;Hostanska et al, 1995), since after lectin depletion the immunomodulating activity disappears (Beuth et al, 1995;Lenartz et al, 2000).…”
Section: Discussionmentioning
confidence: 92%
“…A single galactoside lectin was isolated but it only partially resembles the immunomodulatory effects found for the whole extract (Ferna´ndez et al, 2003). In contrast, the lectins from V. album are the most active components of European mistletoe preparations and are potent apoptosis inducers (Gabius et al, 1992(Gabius et al, , 1994Hajto et al, 1997;Hostanska et al, 1996/97).…”
Section: Introductionmentioning
confidence: 92%
“…for genetic assays) and other eukaryotic cells; trafficking of drugs and other active components to deficient target cells, or cancer cells for their selective damage (Chaudry et al, 1993); efficient vaccines for active and passive immune protection against I! aeruginosa (Gilboa- and other lectin-bearing bacterial infections; immunomodulation, increasing resistance against heterologous bacterial infections (Avichezer and Gilboa- ) and probably also against cancer, like plant lectins (Hajto et al, 1989;Gabius et al, 1992;Gabius, 1994). …”
Section: Referencesmentioning
confidence: 99%